Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Idiopathic (Essential) Hypertension Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Idiopathic (Essential) Hypertension Overview | 9 | 1 |
| Idiopathic (Essential) Hypertension Therapeutics under Development by Companies | 10 | 1 |
| Idiopathic (Essential) Hypertension Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Idiopathic (Essential) Hypertension Products under Development by Companies | 14 | 1 |
| Idiopathic (Essential) Hypertension Companies Involved in Therapeutics Development | 15 | 11 |
| Actelion Ltd | 15 | 1 |
| Bayer AG | 16 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 17 | 1 |
| Daiichi Sankyo Company, Limited | 18 | 1 |
| Eli Lilly and Company | 19 | 1 |
| HanAll Biopharma Co., Ltd. | 20 | 1 |
| Innopharmax Inc. | 21 | 1 |
| Lee's Pharmaceutical Holdings Limited | 22 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 23 | 1 |
| Quantum Genomics SA | 24 | 1 |
| Takeda Pharmaceutical Company Limited | 25 | 1 |
| Idiopathic (Essential) Hypertension Therapeutics Assessment | 26 | 10 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Combination Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 21 |
| (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) Drug Profile | 36 | 1 |
| (amlodipine besylate + candesartan cilexetil) Drug Profile | 37 | 2 |
| (atorvastatin calcium + losartan potassium) Drug Profile | 39 | 1 |
| (candesartan cilexetil + nifedipine) Drug Profile | 40 | 1 |
| azilsartan medoxomil Drug Profile | 41 | 2 |
| carvedilol phosphate CR Drug Profile | 43 | 1 |
| CS-3150 Drug Profile | 44 | 2 |
| lisinopril Drug Profile | 46 | 1 |
| LY-2623091 Drug Profile | 47 | 1 |
| PB-1046 Drug Profile | 48 | 2 |
| PB-1120 Drug Profile | 50 | 1 |
| QGC-001 Drug Profile | 51 | 3 |
| rostafuroxin Drug Profile | 54 | 2 |
| Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension Drug Profile | 56 | 1 |
| Idiopathic (Essential) Hypertension Dormant Projects | 57 | 2 |
| Idiopathic (Essential) Hypertension Product Development Milestones | 59 | 2 |
| Featured News &Press Releases | 59 | 1 |
| Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure | 59 | 1 |
| Jun 12, 2013: Lee s Pharma Enrolls First Patient in Phase IIb Clinical Trial of Rostafuroxin in Italy | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |